Olverembatinib tablets are white or off-white round tablets. They should be protected from light, sealed, and stored at temperatures not exceeding 25°C.
Side Effects of Olverembatinib
Common adverse reactions that may occur include:
Blood-related: thrombocytopenia, anemia, leukopenia, neutropenia (incidence rate reaching or exceeding 10%);
Metabolic abnormalities: hypertriglyceridemia (elevated triglyceride levels in the blood), hypocalcemia, hyperglycemia, hypokalemia, hyponatremia;
Organ function indicator abnormalities: proteinuria (elevated protein content in urine), increased blood bilirubin, increased gamma-glutamyl transferase;
Physical symptoms: skin darkening, fever, muscle pain, limb pain, rapid heartbeat, rash.
The incidence rate of more serious adverse reactions is approximately 19.4%
Severe thrombocytopenia (8.5%)
Severe anemia (3.1%)
Infectious pneumonia (1.6%)
Approximately 22.9% of people will experience reactions requiring a dosage reduction
Marked thrombocytopenia (14.7%)
Severe neutropenia (3.4%)
Significant leukopenia (2.2%)
Worsening anemia (1.6%)
Increased creatine phosphokinase (1.3%)
Everyone's physical condition is different, and the severity of reactions will also vary. During the medication period, special attention should be paid to observing physical changes, and any discomfort symptoms should be promptly reported to a doctor. The doctor may recommend regular measurements of indicators such as blood pressure, heart rate, and respiratory rate to ensure timely detection and management of problems.
Under what circumstances should Olverembatinib tablets be stopped immediately?
Vascular occlusion symptoms: If symptoms of suspected thrombosis, such as sudden limb numbness or chest pain, appear, medication must be stopped immediately for observation, and resumption of treatment should only be considered after symptoms subside.
Blood indicator abnormalities: When a routine blood test reveals a significant decrease in blood cells, medication must be temporarily suspended according to the doctor's advice, waiting for the indicators to return to normal.
Liver function abnormalities: If transaminases (ALT/AST) or gamma-GGT exceed 2.5 times the upper limit of normal before treatment, administration should be postponed until the indicators return to normal. Liver function should be checked at least once a month during the treatment process; if severe abnormalities (Grade 3 or above) occur, medication must be stopped immediately for treatment, and the frequency of checks should be increased until recovery.
Severe hypertension: If blood pressure rises to Grade 3 or Grade 4 levels (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg), treatment needs to be temporarily suspended.
Any discomfort symptoms: If significant discomfort persists after discontinuing the medication, seek medical attention promptly. The doctor will evaluate whether permanent discontinuation or adjustment of the treatment plan is necessary based on specific circumstances.
Before resuming medication each time, it must be confirmed that relevant indicators or symptoms have returned to a safe range. Close communication with the doctor and timely completion of all examinations must be maintained throughout the entire treatment process.
